Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00302276|
Recruitment Status : Completed
First Posted : March 14, 2006
Last Update Posted : January 21, 2009
|Condition or disease||Intervention/treatment||Phase|
|Obesity||Drug: Metobes-compound||Phase 2 Phase 3|
It has previously been shown that a combination of tyrosine, capsaicin, catechines, and caffeine may stimulate the sympathetic nervous system and promote satiety, lipolysis and thermogenesis. In addition, dietary calcium may increase fecal fat excretion.
80 healthy Danish overweight to obese (BMI between 28 and 35 kg/m2), 18 to 70 years of age subjects of both gender. All subjects was be weight stable (within 3-kg) 2 months prior to study inclusion, non-smoking, non-athletic and have no daily use of medication except for anticonception and antihypertensive compounds. All subjects gave their written consent after verbal and written information about the study. The study protocol was approved by The Municipal Ethical Committee of Copenhagen and Frederiksberg as being in accordance with the Helsinki II Declaration.
The total study period was 12 weeks. The intervention design was an 8-weeks randomized, 3-arm parallel, placebo-controlled and double-blind intervention. Prior to the randomized intervention a weight loss was initiated by 4 week treatment on a 3.4 MJ/d low caloric diet (LCD). Only subject who lost more than 4% of their initial body weight after 4 weeks LCD treatment was randomized and continued in the study.
The subjects were randomized into 3 balanced groups i.e. placebo, simple or enterocoated release. All subjects received dietary instruction to a slightly hypo caloric diet of -300 kcal/day after the isoenergetic educational system. The dietary advice was reinforced by dietetic consultations every fortnight.
Body weight and composition were assessed by DEXA before and after the LCD period, four weeks into the randomized period and at completion i.e. the last day of the study.
All participants underwent assessment of energy expenditure by indirect calorimetry in a ventilated hood. The first respiratory measurement was on the first day of the intervention and will last for 5 hours.
All subjects collected all feces excreted three days prior to respiratory measurement and one day of urine excreted.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)|
|Study Start Date :||January 2004|
|Estimated Study Completion Date :||July 2004|
- Body weight, fat mass, fat free mass, energy expenditure, respiratory quotient, fecal fat, fecal energy
- blood pressure, heart rate, urine catecholamines, self-reported adverse events
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00302276
|Department of Human Nutrition, The Royal Veterinary and Agricultural University|
|Frederiksberg, Denmark, 1958|
|Principal Investigator:||Jens Kondrup, Prof||Department of Human Nutrition, The Royal Veterinary and Agricultural University, Denmark|